PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.1523
https://www.valueinhealthjournal.com/article/S1098-3015(12)03236-6/fulltext
Section Title :
Research on Methods
Section Order :
1023
First Page :
A471
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03236-6&doi=10.1016/j.jval.2012.08.1523